drugset / Trial / NCT00621036
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with CNS lymphoma.
Timeline
- Start
- 2007-10-19
- Primary completion
- 2008-12-08
- Completion
- 2008-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Id-KLH | Vaccine | — | Subcutaneous |
| Background | Methotrexate | Small molecule | — | Intravenous |
| Background | Thiotepa | Other / unclassified | — | Other |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |